PMOS: The New Name for PCOS – Why Polycystic Ovary Syndrome Has Been Renamed

For many years, women diagnosed with PCOS (Polycystic Ovary Syndrome) have associated the condition primarily with ovarian cysts and reproductive health. However, the medical community is now introducing a new term: PMOS (Polyendocrine Metabolic Ovarian Syndrome).

Importantly, this is not a new disease or a change in diagnosis. Rather, it is a change in terminology intended to more accurately reflect the true nature of this complex condition.

Is PCOS Becoming a Thing of the Past?

Individuals previously diagnosed with PCOS still have the same medical condition. The underlying disorder has not changed—only its name. Diagnostic criteria, clinical manifestations, and treatment principles remain fundamentally the same.

For decades, the term Polycystic Ovary Syndrome implied that ovarian cysts were the defining feature of the disorder. In reality, this has been one of the greatest misconceptions surrounding PCOS. Many patients do not exhibit the classic ultrasound appearance traditionally associated with “polycystic ovaries,” and the structures often described as cysts are, in fact, immature ovarian follicles rather than true ovarian cysts.

Why Has PCOS Been Renamed PMOS?

The new term, Polyendocrine Metabolic Ovarian Syndrome (PMOS), recognizes that the condition extends far beyond the ovaries. It affects multiple physiological systems, including endocrine function, metabolism, reproductive health, dermatological health, body weight regulation, and psychological well-being.

The acronym PMOS reflects these broader clinical features:

• Polyendocrine – highlighting the involvement of multiple endocrine pathways.
• Metabolic – emphasizing the central role of metabolic dysfunction, particularly insulin resistance.
• Ovarian – acknowledging the condition’s impact on ovarian function.
• Syndrome – indicating a constellation of related clinical features rather than a single disease process.

The revised terminology encourages both clinicians and patients to view the condition holistically. For many years, PCOS was considered primarily a gynecological disorder affecting menstruation and fertility, whereas current evidence clearly demonstrates that it is a multisystem endocrine and metabolic disorder.

Clinical Features of PMOS

Although the name has changed, the clinical presentation remains the same as that previously described for PCOS. The syndrome is highly heterogeneous, meaning that symptoms vary considerably between individuals.

Common manifestations include:

• irregular menstrual cycles or anovulation,
• infertility or difficulty conceiving,
• hirsutism,
• acne,
• oily skin,
• androgenic hair thinning,
• difficulty maintaining a healthy body weight,
• insulin resistance and other disturbances of glucose metabolism.

Two individuals with PMOS may present with entirely different symptom profiles. One patient may experience predominantly dermatological symptoms, another may struggle mainly with menstrual irregularities, while another may exhibit primarily metabolic complications. This marked clinical diversity was one of the driving forces behind the adoption of a more representative name.

Does PMOS Carry Greater Health Risks?

The name change also highlights an important clinical reality: PMOS is not solely a reproductive disorder.

For many patients, the syndrome is associated with an increased risk of metabolic complications, including insulin resistance, type 2 diabetes mellitus, dyslipidemia, and cardiovascular disease.

Historically, both patients and healthcare professionals often focused primarily on fertility and menstrual symptoms. However, long-term management should also include regular assessment of metabolic health, cardiovascular risk factors, lifestyle, and overall well-being.

The term PMOS reinforces the need for comprehensive, multidisciplinary care involving not only gynecologists but frequently endocrinologists, dietitians, and other healthcare professionals.

Do Patients Need to Be Re-Diagnosed?

In short, no.

The introduction of the term PMOS does not require repeat diagnostic testing or reassessment. Individuals previously diagnosed with PCOS retain their diagnosis.

As with any change in medical terminology, a transitional period is expected. Medical records, scientific literature, educational resources, and routine clinical practice will continue to use both PCOS and PMOS for some time. Patients may therefore encounter both terms interchangeably.

Will the New Name Make a Difference?

For many patients, the greatest value of the new terminology lies in shifting the understanding of the condition.

The name Polycystic Ovary Syndrome often reinforced the misconception that the disorder primarily involved ovarian cysts. In contrast, Polyendocrine Metabolic Ovarian Syndrome better reflects its complex endocrine and metabolic nature.

A more accurate name has the potential to improve disease awareness, facilitate earlier diagnosis, and promote a more comprehensive approach to treatment. This is particularly important for individuals who have spent years searching for an explanation for seemingly unrelated symptoms that ultimately share a common underlying cause.

A New Chapter in Women’s Health

The transition from PCOS to PMOS illustrates how medical terminology evolves alongside scientific understanding.

While a change in name may appear largely symbolic, terminology influences clinical practice, research priorities, physician awareness, and patient education. At LuMedic, we recognize the importance of accurately describing conditions to improve understanding and optimize patient care.

PMOS reminds us that this syndrome extends far beyond ovarian involvement. It is a complex endocrine and metabolic disorder that requires individualized, multidisciplinary management.

Although PCOS and PMOS describe the same clinical condition, the new terminology provides a more complete and scientifically accurate representation of its true nature.

Source: The Lancet. Redefining PCOS as Polyendocrine Metabolic Ovarian Syndrome (PMOS). 2026.

Authors: